Aimmune Therapeutics Inc. (AIMT)

22.82
NASDAQ : Health Technology
Prev Close 22.61
Day Low/High 21.86 / 22.85
52 Wk Low/High 21.47 / 42.00
Avg Volume 617.30K
Exchange NASDAQ
Shares Outstanding 58.73M
Market Cap 1.38B
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

I'm Surprised by How Lifeless the Action Is

I'm Surprised by How Lifeless the Action Is

I find it difficult to believe that there won't be something positive out of the G-20 meeting.

Aimmune Therapeutics Announces Closing Of $98 Million Investment By Nestlé Health Science

Aimmune Therapeutics Announces Closing Of $98 Million Investment By Nestlé Health Science

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Science.

First Week Of AIMT January 2019 Options Trading

First Week Of AIMT January 2019 Options Trading

Investors in Aimmune Therapeutics Inc saw new options begin trading this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.

AIMT: Insiders Vs. Shorts

AIMT: Insiders Vs. Shorts

The most recent short interest data was recently released for the 10/31/2018 settlement date, and Aimmune Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 14.17 "days to cover" versus the median component at 4.44. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Kohl's Stock Finds Itself Under Heavy Pressure

Kohl's Stock Finds Itself Under Heavy Pressure

The problem KSS faces is that reports from retailers are being automatically sold in this poor market right now.

Landmark PALISADE Trial Of AR101 Published In New England Journal Of Medicine

Landmark PALISADE Trial Of AR101 Published In New England Journal Of Medicine

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the New England Journal of Medicine ( NEJM) has published the full results of the landmark...

Aimmune Therapeutics Announces Additional Equity Investment By Nestlé Health Science

Aimmune Therapeutics Announces Additional Equity Investment By Nestlé Health Science

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Nestlé Health Science will make an additional equity investment in Aimmune of $98 million,...

Aimmune Therapeutics Announces Third Quarter 2018 Financial Results And Recent Corporate Highlights

Aimmune Therapeutics Announces Third Quarter 2018 Financial Results And Recent Corporate Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2018.

Aimmune Therapeutics Announces Presentations At 2018 ACAAI Annual Scientific Meeting

Aimmune Therapeutics Announces Presentations At 2018 ACAAI Annual Scientific Meeting

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on AR101, oral immunotherapy and peanut allergy at the American College...

Aimmune Therapeutics Announces Appointment Of Dr. Brett Haumann To Board Of Directors

Aimmune Therapeutics Announces Appointment Of Dr. Brett Haumann To Board Of Directors

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann, M.

Aimmune Therapeutics To Participate In Upcoming Investor Conferences

Aimmune Therapeutics To Participate In Upcoming Investor Conferences

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will participate in the following investor conferences: Stifel 2018...

Aimmune Therapeutics Announces Initiation Of Phase 2 Study With Regeneron And Sanofi Of AR101 With Adjunctive Dupilumab In Peanut-Allergic Patients

Aimmune Therapeutics Announces Initiation Of Phase 2 Study With Regeneron And Sanofi Of AR101 With Adjunctive Dupilumab In Peanut-Allergic Patients

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron and Sanofi, of AR101 with adjunctive dupilumab...

My Options Strategy for These 2 Biotech Stocks

My Options Strategy for These 2 Biotech Stocks

It's weeks like this that I'm glad I have some 'dry powder' to deploy.

First Week Of AIMT November 16th Options Trading

First Week Of AIMT November 16th Options Trading

Investors in Aimmune Therapeutics Inc saw new options begin trading this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new November 16th contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics To Present At The Cantor Global Healthcare Conference On Wednesday, October 3

Aimmune Therapeutics To Present At The Cantor Global Healthcare Conference On Wednesday, October 3

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that President and CEO Jayson Dallas, M.

First Week Of AIMT October 19th Options Trading

First Week Of AIMT October 19th Options Trading

Investors in Aimmune Therapeutics Inc saw new options begin trading this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new October 19th contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics To Present At Three Investor Conferences In September

Aimmune Therapeutics To Present At Three Investor Conferences In September

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will present at three investor conferences in September: Wells Fargo...

Aimmune Therapeutics Announces Second Quarter 2018 Financial Results

Aimmune Therapeutics Announces Second Quarter 2018 Financial Results

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2018.

Aimmune Therapeutics Announces CEO Jayson Dallas Will Present At The Wedbush PacGrow Healthcare Conference On Wednesday, August 15th

Aimmune Therapeutics Announces CEO Jayson Dallas Will Present At The Wedbush PacGrow Healthcare Conference On Wednesday, August 15th

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.

Aimmune Therapeutics: An Interesting Business and Charts to Watch

Aimmune Therapeutics: An Interesting Business and Charts to Watch

Let's check out the charts and indicators.

The Name of the Game Is Growth: Cramer's 'Mad Money' Recap (Wednesday 6/20/18)

The Name of the Game Is Growth: Cramer's 'Mad Money' Recap (Wednesday 6/20/18)

Jim Cramer explains why the fulcrum for the financial markets is growth -- not tariffs, or the Fed, or interest rates.

Aimmune Therapeutics Appoints Dr. Jayson Dallas As CEO

Aimmune Therapeutics Appoints Dr. Jayson Dallas As CEO

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the appointment of Jayson Dallas, M.

Aimmune Therapeutics Announces Data On Terminology Used With Oral Immunotherapy Were Presented At EAACI 2018

Aimmune Therapeutics Announces Data On Terminology Used With Oral Immunotherapy Were Presented At EAACI 2018

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that data on terminology used with oral immunotherapy were presented at the European Academy of...

Aimmune Therapeutics Announces New Clinical Data On AR101 For Peanut Allergy At The 2018 EAACI Congress

Aimmune Therapeutics Announces New Clinical Data On AR101 For Peanut Allergy At The 2018 EAACI Congress

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, reported additional results from its pivotal Phase 3 PALISADE trial of AR101 for the treatment of peanut allergy...

First Week Of AIMT July 20th Options Trading

Investors in Aimmune Therapeutics Inc saw new options become available this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics To Present Data On Peanut Allergy At The European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2018

Aimmune Therapeutics To Present Data On Peanut Allergy At The European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2018

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on peanut allergy at the European Academy of Allergy and Clinical...

Many Names on My Radar

Many Names on My Radar

There is no question that we are becoming extended and ripe for some profit taking.